A compelling review reveals voluntary medical male circumcision (VMMC) safeguards women’s sexual and reproductive health, slashing risks of cervical cancer, HPV, HSV-2, and bacterial vaginosis (BV). Beyond HIV prevention in men, it benefits female partners through microbiome shifts and lower STI transmission. Women report higher sexual satisfaction and perceive better hygiene, without risky behavior increases.
Review Highlights
VMMC cuts heterosexual HIV risk by 60% in men and protects against STIs like HPV and genital ulcers. For women, systematic evidence shows reduced cervical dysplasia, cancer, HSV-2, chlamydia, and syphilis. Emerging data links it to lower trichomoniasis and BV risks, tied to penile microbiome changes reducing harmful anaerobes.
Post-2016 studies, including South African surveys and VOICE trial, confirm protections: HSV-2 (aOR 0.71), HIV (aOR 0.66), syphilis (aHR 0.52). No links to gonorrhea or mycoplasma, but gaps persist for trichomoniasis and mycoplasma genitalium. Modeling predicts VMMC averts thousands of cervical cancer cases in Uganda and Tanzania by 2070.
Key Health Wins
HPV protection stands out: VMMC halves men’s acquisition, correlating with women’s lower oncogenic strains and cervical cancer. BV drops via microbiome harmony—penile anaerobes like Prevotella fall post-circumcision, predicting 27% vs. 37% BV incidence in partners.
Sexual satisfaction improves: Rakai trial women reported 40% better pleasure post-partner circumcision, 57% no change. Kenyan survey: 90-97% see circumcised partners as lower HIV/STI risk, more enjoyable sex, easier hygiene. No risk compensation—condom use steady.
| STI/Outcome | Protection Level | Key Evidence |
|---|---|---|
| Cervical Cancer | High (modeling: 20-30% drop) | HPV reduction in couples |
| HSV-2 | Strong (aOR 0.71) | Household surveys, trials |
| Syphilis | Likely (aHR 0.52) | VOICE trial |
| BV | Consistent (RR 0.69) | Kenyan cohort |
| HPV Oncogenic | High (systematic reviews) | Genotype correlation |
This table spotlights encouraging reductions, empowering couples.
Microbiome Magic
VMMC transforms penile bacteria, slashing BV-linked anaerobes (e.g., Gardnerella, Dialister). Kenyan study: penile profile predicts partner’s BV with 78% accuracy up to a year later. Couples show microbiome similarity, higher in BV cases—circumcision disrupts harmful transfer.
Gaps: No direct fertility/pregnancy studies, despite non-Lactobacillus microbiomes risking preterm birth. Lactobacillus crispatus dominance aids fertility; VMMC may foster this indirectly.
Women’s Perceptions
Kenyan women overwhelmingly favor circumcision: 92% think lower HIV risk, 90-97% better sex enjoyment/cleanliness. No function decline in men; meta-analyses confirm satisfaction holds.
| Perception | Circumcised Partner (%) | Uncircumcised (%) | P-value |
|---|---|---|---|
| Easier HIV prevention | 92 | 90 | 0.57 |
| More sex enjoyment | 90 | 97 | 0.04 |
| Vagina cleaner | 92 | 91 | 0.95 |
| Fewer injuries/STIs | 89-94 | 86-93 | >0.5 |
Practices safe: Similar condom use (14-19%), partners, sex acts.
Future Promise
Couples-based HIV/STI strategies succeed; VMMC fits perfectly. Prioritize penile microbiome research for BV/fertility therapies. In sub-Saharan Africa, where BV/preterm risks loom, VMMC optimizes outcomes.
This review urges trials on mycoplasma/trichomonas, pregnancy links. Benefits extend globally, blending biology with perceptions for healthier intimacy.
Reference: here
Other Articles:
